APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside

Key Takeaways

• Expansion into rare kidney diseases and strong leadership in eye disease treatments set the stage for revenue growth and increased market reach.
  
• Enhanced balance sheet and operational efficiency enable greater investment in R&D and commercialization, supporting profitability and long-term earnings potential.
  
• Revenue and profitability face multiple pressures from access barriers, intense competition, costly R&D, and potential regulatory or policy-driven pricing constraints.

Catalysts

A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.

• The recent FDA label expansion for EMPAVELI into rare kidney diseases (C3G and IC-MPGN), along with active plans to launch and pursue additional indications (FSGS and DGF), positions Apellis to access larger patient pools and accelerate long-term topline growth, driven by the increasing prevalence of rare and age-associated diseases. This is likely to result in higher future revenues and market diversification.
  
• SYFOVRE maintains strong market leadership in geographic atrophy (GA), with over 60% market share and only ~10% market penetration to date, leaving significant runway for patient expansion as the global population ages and adoption among specialists and general ophthalmologists rises. Steady injection growth and broader awareness should drive increasing revenues over the long term.
  
• A maturing, innovative pipeline, demonstrated by the initiation of next-generation therapies (e.g., SYFOVRE + ATL-3007 combination), offers embedded optionality for new differentiated product launches and increased R&D productivity, supporting sustained long-term earnings growth if successfully commercialized.
  
• Recent deals, such as the capped royalty purchase agreement with Sobi, strengthened Apellis' balance sheet with substantial upfront cash and limited downside royalty exposure, enabling further investment in operational efficiency, R&D, and commercialization. This lays the foundation for expanding gross margins and driving sustainable future profitability.
  
• Improving operational efficiency (evidenced by reduced operating expenses year-over-year despite ongoing launches and R&D investment) signals that as manufacturing and distribution scale, incremental revenues from current and future products should meaningfully enhance net margins and overall earnings leverage over time.

Apellis Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Apellis Pharmaceuticals's revenue will grow by 16.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -30.2% today to 10.8% in 3 years time.
• Analysts expect earnings to reach $130.6 million (and earnings per share of $0.89) by about September 2028, up from $-228.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $434.9 million in earnings, and the most bearish expecting $-116.7 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 47.5x on those 2028 earnings, up from -15.4x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
• Analysts expect the number of shares outstanding to grow by 1.52% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.84%, as per the Simply Wall St company report.

Apellis Pharmaceuticals Future Earnings Per Share Growth

Risks

• Heavy utilization of free drug and persistent funding shortages for co-pay assistance programs are materially impacting current revenues and may persist throughout the year, putting pressure on net revenue and potentially lowering near-term and medium-term net margins if patient access issues are not resolved.
  
• Reliance on continued steady growth of SYFOVRE in a market with only 10% current penetration, against competitors projecting much higher market growth and potential for meaningful label expansion, heightens the risk that lower-than-anticipated adoption or loss of market share could temper revenue and earnings growth long-term.
  
• The company is investing heavily in R&D for label expansion and pipeline development, but failure to achieve successful pivotal trial outcomes in new indications (e.g., FSGS, DGF) would result in sustained high expenses without corresponding revenue increases, restricting future earnings and delaying profitability.
  
• Competitive landscape in both GA and rare nephrology indications is intensifying, with other companies actively pursuing studies for label expansion, which could lead to pricing pressure, reduced revenue per patient, or the need for significant rebates/concessions, directly compressing net margins.
  
• Long-term sustainability and financial health are at risk if healthcare policy trends toward further cost-containment, government price negotiations, or more restrictive reimbursement frameworks, all of which could cap Apellis's ability to price its therapies at a premium, suppressing revenue growth and overall profitability.

Valuation

• The analysts have a consensus price target of $38.556 for Apellis Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $19.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.2 billion, earnings will come to $130.6 million, and it would be trading on a PE ratio of 47.5x, assuming you use a discount rate of 6.8%.
• Given the current share price of $27.8, the analyst price target of $38.56 is 27.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.